This ongoing dialogue ensures that the medication is working effectively and safely, allowing for the best possible outcomes
What began as a once-weekly injectable GLP-1 receptor agonist for type 2 diabetes (Ozempic, approved 2017) has evolved into a multi-formulation, multi-indication therapeutic platform with three commercially marketed products: Ozempic (injectable, diabetes + cardiovascular + CKD), Wegovy (injectable, obesity + cardiovascular + MASH), and Rybelsus (oral tablet, diabetes + cardiovascular + obesity)
With our Advantage, you receive Wellness Sessions, Personalized Nutrition, Community Support, and Exclusive NAD+ pricing
Clear, colorless solution is the expected appearance for properly compounded semaglutide
While theres no real health risk to simply stopping the medication, titrating can be beneficial for many patients
In a trial of adult patients with type 2 diabetes and BMI greater than or equal to 27 kg/m2 for weight reduction (Study 3), diabetic retinopathy was reported by 4% of WEGOVY injection-treated patients and 2.7% placebo-treated patients [see Clinical Studies (14.2)]